Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1150 of 1463 entries
View as:

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT06848569 Org: User:
Start: 10/23/24 End: 10/23/31 Due: 10/23/32

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Phase: N/A Priority: Normal
NCT ID: NCT04254640 Org: User:
Start: 03/01/21 End: 12/31/23 Due: 12/31/24

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

Phase: N/A Priority: Normal
NCT ID: NCT04624958 Org: User:
Start: 12/01/20 End: 12/31/26 Due: 12/31/27

Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01068067 Org: User:
Start: 03/31/10 End: - Due: -

FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02128425 Org: User:
Start: 04/30/14 End: 04/30/18 Due: 04/30/19

Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05193617 Org: User:
Start: 01/20/22 End: 01/01/27 Due: 01/01/28

Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03855020 Org: User:
Start: 05/09/19 End: 05/01/24 Due: 05/01/25

Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT

Phase: N/A Priority: Normal
NCT ID: NCT03283293 Org: User:
Start: 02/28/01 End: 04/30/08 Due: 04/30/09

Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04472403 Org: User:
Start: 11/26/19 End: 12/31/20 Due: 12/31/21

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05949944 Org: User:
Start: 08/15/23 End: 12/31/26 Due: 12/31/27

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT03812770 Org: User:
Start: 08/04/18 End: 09/01/19 Due: 09/01/20

Evaluation of COVID-19 Immune Barrier and Reinfection Risk

Phase: N/A Priority: Normal
NCT ID: NCT05774093 Org: User:
Start: 03/06/23 End: 07/31/27 Due: 07/31/28

Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00744302 Org: User:
Start: 04/30/06 End: 12/31/09 Due: 12/31/10

A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03257735 Org: User:
Start: 05/01/17 End: 05/31/19 Due: 05/31/20

Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT01409499 Org: User:
Start: 01/31/11 End: 01/31/18 Due: 01/31/19

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03904563 Org: User:
Start: 01/01/19 End: 12/15/22 Due: 12/15/23

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02066038 Org: User:
Start: 01/31/14 End: 03/31/16 Due: 03/31/17

Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05573282 Org: User:
Start: 10/16/22 End: 01/01/26 Due: 01/01/27

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05742750 Org: User:
Start: 03/01/23 End: 12/30/24 Due: 12/30/25

The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02407522 Org: User:
Start: 06/30/14 End: 12/31/14 Due: 12/31/15

Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03318419 Org: User:
Start: 01/01/16 End: 12/31/20 Due: 12/31/21

A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT03932006 Org: User:
Start: 06/30/16 End: 05/31/19 Due: 05/31/20

An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus

Phase: N/A Priority: Normal
NCT ID: NCT06730672 Org: User:
Start: 12/30/24 End: 12/27/28 Due: 12/27/29

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04453826 Org: User:
Start: 09/01/20 End: 09/30/28 Due: 09/30/29

Developmental Profile of Ocular Refraction in Patients With Congenital Cataract

Phase: N/A Priority: Normal
NCT ID: NCT02761850 Org: User:
Start: 01/31/10 End: 01/31/16 Due: 01/31/17